



Crescendo Biologics' CEO, Peter Pack, to present at 9th Annual PEGS Europe 14 November 2017

Cambridge, UK, 10 November 2017 – Crescendo Biologics Limited (Crescendo), the drug developer of Humabody[®] therapeutics, announces that its CEO, Peter Pack, will be presenting at the 9th Annual PEGS Europe in Lisbon, Portugal on 14 November 2017.

PEGS Europe Protein & Antibody Engineering Summit is being held in Lisbon from 13 – 17 November. Peter Pack, Crescendo's CEO, will present on the Discovery and Development of Topically Applied Biologics within the "Novel Approaches for Immunotherapy Against Autoimmune Disease and Beyond" section.

Title: Discovery and Development of Topically Applied Biologics for the Treatment of Mild-to Moderate Psoriasis Based on a Transgenic Platform Producing 100% Human VHs, Rescued and Selected by Phage Display

Date: Tuesday 14 November 2017

Time: 15:15

Location: EPIC SANA, Lisboa Hotel, Avenida Engenheiro Duarte Pacheco 15, 1070-100 Lisbon, Portugal

For more information on Crescendo's presentation or for media enquiries, please contact crescendo@instinctif.com.

Ends

For more information, please contact:

Crescendo Biologics Dr Peter Pack, CEO	Tel:44 (0)1223 497140 info@crescendobiologics.com
Instinctif Partners Dr Christelle Kerouedan / Melanie Toyne-Sewell	Tel:44 (0)20 7457 2020 crescendo@instinctif.com

Notes to Editors:

About Crescendo Biologics Ltd



Crescendo Biologics is a biopharmaceutical company discovering and developing potent, highly differentiated mono- and multi-specific Humabody[®] therapeutics in oncology. The Company's Humabody[®] therapeutics are based on its unique, patent protected, transgenic mouse platform generating 100% human V_H domain building blocks (Humabody[®] V_H) with superior biophysical properties.

Crescendo is pursuing novel Humabody[®]-based product opportunities, through in-house development and strategic partnerships in both multi-specific immuno-oncology modulators and HDCs (Humabody[®] Drug Conjugates), the next generation of ADCs.

Crescendo is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova Partners, Touchstone Innovations (formerly known as Imperial Innovations) and Takeda.

For more information, please visit the website: www.crescendobiologics.com.